Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/218158
Title: | Neurocognitive and clinical profile of male patients with substance use disorder in early remission phase with and without comorbid depression |
Author: | Marquez Arrico, Julia E. Catalán-Aguilar, Judit Navarro, José Francisco Adan Puig, Ana |
Keywords: | Abús de substàncies Psicopatologia Depressió psíquica Cognició Homes Substance abuse Pathological psychology Mental depression Cognition Men |
Issue Date: | 16-Jul-2024 |
Publisher: | Elsevier B.V. |
Abstract: | Substance Use Disorder (SUD) represents one of the most frequent conditions worldwide which commonly coexists with major depressive disorder (MDD). This comorbidity (SUD + MDD) is one of the most prevalent with patients showing certain social and clinical characteristics that could lead to a worsening of their cognitive performance. However, despite these particularities, only a few studies have addressed the possible differences in cognitive performance between patients with SUD + MDD compared with those with SUD-only patients. Therefore, the aim of this study is to examine the clinical and cognitive profile of patients with SUD + MDD vs. SUD-only who are in early remission phase. For this purpose, 271 male patients underwent a clinical and neuropsychological assessment (SUD + MDD group: N = 101; SUD-only group: N = 170). Results indicated that SUD + MDD patients showed worse cognitive performance than SUD in visuospatial reasoning, verbal memory and learning, recognition, and processing speed even after a 3-month period of abstinence. Furthermore, these patients exhibited more self-reported prefrontal symptoms, as well as worse social and clinical conditions. This study indicates that the neurocognitive and clinical profile of patients with SUD + MDD could represent a risk since their characteristics have been associated with poorer recovery and prognosis. Our results could be helpful in clinical practice highlighting the need for cognitive remediation strategies in these populations, providing information that would allow the implementation of more appropriate treatments and preventive strategies. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.pnpbp.2024.111085 |
It is part of: | Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2024, vol. 134, 111085 |
URI: | https://hdl.handle.net/2445/218158 |
Related resource: | https://doi.org/10.1016/j.pnpbp.2024.111085 |
ISSN: | 0278-5846 |
Appears in Collections: | Articles publicats en revistes (Psicologia Clínica i Psicobiologia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
874988.pdf | 491.45 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License